NATCO Pharma Shares Plunge 14.7% as Q3 Profit Nosedives 37%

NATCO Pharma's shares tumbled 14.7% in pre-open trade on Thursday, February 13, 2025, following a disappointing Q3 FY2024-25 earnings report. The pharmaceutical giant's net profit plummeted 37% year-on-year to Rs 132.4 crore, falling short of analyst expectations. Revenue also declined sharply by 37.4% to Rs 474.80 crore, while EBITDA crashed 86% to Rs 38.79 crore. The company's margin contracted significantly to 8.2% from 35.3% in the same quarter last year. Despite challenges, NATCO Pharma's board declared a third interim dividend of Rs 1.50 per equity share for FY2024-25.

Sources: Economic Times, NDTV Profit